Revolution Medicines secures first broad RAS approval in pancreatic cancer
The FDA cleared Revolution Medicines' RASONQUE on August 26, making it the first broad RAS-targeted therapy for metastatic pancreatic adenocarcinoma.
Revolution Medicines
Every Fin-node story mentioning Revolution Medicines — 1 story, newest first.
Revolution Medicines · 1 story